Clinical Trials Logo

Filter by:
NCT ID: NCT02299505 Completed - Clinical trials for Non-Small Cell Lung Cancer

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Start date: April 9, 2015
Phase: Phase 1
Study type: Interventional

A Phase I study to assess the systemic exposure, effiacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

NCT ID: NCT02299089 Completed - Clinical trials for Neuroendocrine Tumors

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid symptoms.

NCT ID: NCT02297945 Completed - Cushing's Syndrome Clinical Trials

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

PROMPT
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.

NCT ID: NCT02296424 Completed - Clinical trials for Systemic Juvenile Idiopathic Arthritis (SJIA)

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

ß-SPECIFIC 4
Start date: November 17, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.

NCT ID: NCT02296411 Completed - Asthma Clinical Trials

Efficacy of LAMA Added to ICS in Treatment of Asthma

ELITRA
Start date: November 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the superiority of the glycopyrrolate bromide (CHF 5259 pMDI) versus placebo on top of QVAR® pMDI, in terms of lung functions parameters, as well as to assess its safety.

NCT ID: NCT02296255 Completed - Cervical Cancer Clinical Trials

Effect of HPV Vaccination on Women Aged 25 Years

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The purposes of this study are to evaluate the effectiveness of vaccination in 25-year old women at the time of their first access to cervical cancer screening, to understand the impact of vaccination on screening activity; to evaluate the immune response following vaccination; to study the dynamics of the infection after vaccination, including the possible change in the frequency of non-vaccine HPV types, to evaluate cytological abnormalities reductions in vaccinated women and to assess if HPV test in urine sample could be a useful non-invasive method to monitor HPV status in younger women.

NCT ID: NCT02296138 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Start date: January 13, 2015
Phase: Phase 3
Study type: Interventional

The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.

NCT ID: NCT02295930 Completed - Clinical trials for Metastatic Colorectal Cancer

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient

MACBETH
Start date: October 2011
Phase: Phase 2
Study type: Interventional

This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.

NCT ID: NCT02295774 Completed - Colorectal Cancer Clinical Trials

Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA

Start date: February 2013
Phase: Phase 2
Study type: Interventional

Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed by histone gamma H2AX analysis, compared to control biopsies.

NCT ID: NCT02295176 Completed - Metabolic Syndrome Clinical Trials

Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome

ARMP-11
Start date: April 2013
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in patients with MetS and increased LV mass. 168 patients will be enrolled in this randomized, double-blind, parallel-group, placebo-controlled trial and treated for 24 weeks.